DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection (Q48080277)

8 February 2018

title

DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection (English)

1 reference

8 February 2018

main subject

Leishmania donovani

object named as

Leishmania donovani

1 reference

2

1 reference

8 February 2018

Craig W. Roberts

4

1 reference

8 February 2018

author name string

Carter KC

1

1 reference

8 February 2018

Campbell SA

3

1 reference

8 February 2018

Nok A

5

1 reference

8 February 2018

Mullen AB

6

1 reference

8 February 2018

McFarlane E

7

1 reference

8 February 2018

language of work or name

English

0 references

publication date

26 March 2007

1 reference

8 February 2018

published in

Vaccine

1 reference

8 February 2018

volume

25

1 reference

8 February 2018

issue

22

1 reference

8 February 2018

page(s)

4502-4509

1 reference

8 February 2018

Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Toxoplasma gondii: DNA vaccination with bradyzoite antigens induces protective immunity in mice against oral infection with parasite cysts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Humoral responses in mice following vaccination with DNA encoding glutathione S-transferase of Fasciola hepatica: effects of mode of vaccination and the cellular compartment of antigen expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Protection against Schistosoma mansoni utilizing DNA vaccination with genes encoding Cu/Zn cytosolic superoxide dismutase, signal peptide-containing superoxide dismutase and glutathione peroxidase enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Toxoplasma gondii dense granule protein 3 (GRA3) is a type I transmembrane protein that possesses a cytoplasmic dilysine (KKXX) endoplasmic reticulum (ER) retrieval motif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation of Escherichia coli by R-Factor DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Tissue granuloma structure-function in experimental visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

T helper (h)1/Th2 and Leishmania: paradox rather than paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

DNA vaccines: progress and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Immunopathogenesis of infection with the visceralizing Leishmania species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generati

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

Host-parasite relationship in murine leishmaniasis: pathophysiological and immunological changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

inferred from DOI database lookup

7 January 2021

based on heuristic

An overview of paediatric leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.014

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2007.03.014

1 reference

8 February 2018

1 reference

8 February 2018